{"protocolSection": {"identificationModule": {"nctId": "NCT00827775", "orgStudyIdInfo": {"id": "STU 102008-042"}, "secondaryIdInfos": [{"id": "NIH K23 HL092297"}], "organization": {"fullName": "University of Texas Southwestern Medical Center", "class": "OTHER"}, "briefTitle": "Mechanisms and Treatment of Intradialytic Hypertension", "officialTitle": "Blood Pressure, Endothelial Cell Dysfunction, and Outcomes in Dialysis Patients", "acronym": "MATCH"}, "statusModule": {"statusVerifiedDate": "2020-10", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2009-06"}, "primaryCompletionDateStruct": {"date": "2010-09", "type": "ACTUAL"}, "completionDateStruct": {"date": "2010-09", "type": "ACTUAL"}, "studyFirstSubmitDate": "2009-01-21", "studyFirstSubmitQcDate": "2009-01-22", "studyFirstPostDateStruct": {"date": "2009-01-23", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2020-10-12", "resultsFirstSubmitQcDate": "2020-10-12", "resultsFirstPostDateStruct": {"date": "2020-11-03", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2020-10-12", "lastUpdatePostDateStruct": {"date": "2020-11-03", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Peter Van Buren", "investigatorTitle": "Associate Professor of Medicine", "investigatorAffiliation": "University of Texas Southwestern Medical Center"}, "leadSponsor": {"name": "University of Texas Southwestern Medical Center", "class": "OTHER"}, "collaborators": [{"name": "National Heart, Lung, and Blood Institute (NHLBI)", "class": "NIH"}]}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "1. To determine in a cross sectional case-controlled cohort study of 50 hemodialysis patients if blood pressure elevations with hemodialysis are associated with decreased endothelial cell function (measured by brachial artery flow mediated dilation and endothelial progenitor cell number), both of which are novel mechanistic markers in the causal pathway for detrimental cardiovascular outcomes; and\n2. To determine if lowering blood pressure with carvedilol in 25 ESRD subjects with blood pressure elevations with hemodialysis can improve endothelial cell dysfunction as a surrogate mechanistic marker for improving cardiovascular outcomes."}, "conditionsModule": {"conditions": ["Intradialytic Hypertension"], "keywords": ["Hypertension", "Hemodialysis"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "NON_RANDOMIZED", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 55, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Control", "type": "NO_INTERVENTION", "description": "Patients without intradialytic hypertension defined as average pre to post hemodialysis SBP falling \\>10 mmhg for more than 4/6 of the last dialysis treatment sessions"}, {"label": "Intervention", "type": "ACTIVE_COMPARATOR", "description": "Patients with intradialytic hypertension defined as average pre to post hemodialysis SBP elevation of \\>10 mmhg for more than 4/6 of the last dialysis treatment sessions", "interventionNames": ["Drug: Carvedilol"]}], "interventions": [{"type": "DRUG", "name": "Carvedilol", "description": "Carvedilol 6.25 mg BID titrated weekly to maximum of 50 mg bid", "armGroupLabels": ["Intervention"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Endothelial Progenitor Cells", "description": "1. ALDH bright cells reported as percentage of mononuclear cells. These were assayed using flow cytometry\n2. CD34/CD133 endothelial progenitor cells reported as percentage of mononuclear cells. These were assayed using flow cytometry", "timeFrame": "12 weeks"}], "secondaryOutcomes": [{"measure": "Flow Mediated Vasodilation", "description": "Measured as percent change in brachial artery diameter from baseline to post shear stress for an individual measurement. Follow up measurements were obtained in intervention subjects 12 weeks later", "timeFrame": "12 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* on hemodialysis \\> 30 days\n* aged 18 to 80 years old\n* ability to provide informed consent\n* Primary nephrologist deems patient is at target dry weight\n* Predialysis SBP \\>140 or postdialysis SBP\\>130\n\nExclusion Criteria:\n\n* Patients with active wounds\n* Blood pressure unable to be measured by routine mechanisms in the upper extremity\n* Change in blood pressure medications in the previous 2 weeks\n* Intolerance of beta or alpha-blockers\n* pregnancy\n* Resting heart rate \\<50\n* Life expectancy \\< 6 months\n* Current therapy with carvedilol or contraindication to carvedilol (ONLY in the intervention arm)", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "80 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Jula K Inrig, MD, MHS", "affiliation": "UT Southwestern Medical Center", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "UTSW Oakcliff Davita Dialysis", "city": "Dallas", "state": "Texas", "zip": "75224", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"facility": "UTSW Dallas East Davita Dialysis (Buckner unit)", "city": "Dallas", "state": "Texas", "zip": "75228", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"facility": "UTS Dallas Dialysis (Elmbrook)", "city": "Dallas", "state": "Texas", "zip": "75247", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}]}, "referencesModule": {"references": [{"pmid": "22700888", "type": "RESULT", "citation": "Inrig JK, Van Buren P, Kim C, Vongpatanasin W, Povsic TJ, Toto R. Probing the mechanisms of intradialytic hypertension: a pilot study targeting endothelial cell dysfunction. Clin J Am Soc Nephrol. 2012 Aug;7(8):1300-9. doi: 10.2215/CJN.10010911. Epub 2012 Jun 14."}, {"pmid": "21757643", "type": "RESULT", "citation": "Inrig JK, Van Buren P, Kim C, Vongpatanasin W, Povsic TJ, Toto RD. Intradialytic hypertension and its association with endothelial cell dysfunction. Clin J Am Soc Nephrol. 2011 Aug;6(8):2016-24. doi: 10.2215/CJN.11351210. Epub 2011 Jul 14."}, {"pmid": "21734087", "type": "RESULT", "citation": "Van Buren PN, Kim C, Toto R, Inrig JK. Intradialytic hypertension and the association with interdialytic ambulatory blood pressure. Clin J Am Soc Nephrol. 2011 Jul;6(7):1684-91. doi: 10.2215/CJN.11041210."}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Control", "description": "Patients without intradialytic hypertension defined as average pre to post hemodialysis SBP falling \\>10 mmhg for more than 4/6 of the last dialysis treatment sessions"}, {"id": "FG001", "title": "Intervention", "description": "Patients with intradialytic hypertension defined as average pre to post hemodialysis SBP elevation of \\>10 mmhg for more than 4/6 of the last dialysis treatment sessions\n\nCarvedilol: Carvedilol 6.25 mg BID titrated weekly to maximum of 50 mg bid"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "25"}, {"groupId": "FG001", "numSubjects": "30"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "25"}, {"groupId": "FG001", "numSubjects": "25"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "5"}]}], "dropWithdraws": [{"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "5"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Control", "description": "Patients without intradialytic hypertension defined as average pre to post hemodialysis SBP falling \\>10 mmhg for more than 4/6 of the last dialysis treatment sessions"}, {"id": "BG001", "title": "Intervention", "description": "Patients with intradialytic hypertension defined as average pre to post hemodialysis SBP elevation of \\>10 mmhg for more than 4/6 of the last dialysis treatment sessions\n\nCarvedilol: Carvedilol 6.25 mg BID titrated weekly to maximum of 50 mg bid"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "25"}, {"groupId": "BG001", "value": "25"}, {"groupId": "BG002", "value": "50"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "55.1", "spread": "7.9"}, {"groupId": "BG001", "value": "53.9", "spread": "11.1"}, {"groupId": "BG002", "value": "54.5", "spread": "9"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "10"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "20"}, {"groupId": "BG001", "value": "20"}, {"groupId": "BG002", "value": "40"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "15"}, {"groupId": "BG001", "value": "16"}, {"groupId": "BG002", "value": "31"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "10"}, {"groupId": "BG001", "value": "9"}, {"groupId": "BG002", "value": "19"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "10"}, {"groupId": "BG001", "value": "9"}, {"groupId": "BG002", "value": "19"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "15"}, {"groupId": "BG001", "value": "16"}, {"groupId": "BG002", "value": "31"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Region of Enrollment", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "25"}, {"groupId": "BG001", "value": "25"}, {"groupId": "BG002", "value": "50"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Endothelial Progenitor Cells", "description": "1. ALDH bright cells reported as percentage of mononuclear cells. These were assayed using flow cytometry\n2. CD34/CD133 endothelial progenitor cells reported as percentage of mononuclear cells. These were assayed using flow cytometry", "populationDescription": "Follow up measurements were only obtained in the intervention subjects receiving carvedilol", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "% of mononuclear cells", "timeFrame": "12 weeks", "groups": [{"id": "OG000", "title": "Control", "description": "Patients without intradialytic hypertension defined as average pre to post hemodialysis SBP falling \\>10 mmhg for more than 4/6 of the last dialysis treatment sessions"}, {"id": "OG001", "title": "Intervention", "description": "Patients with intradialytic hypertension defined as average pre to post hemodialysis SBP elevation of \\>10 mmhg for more than 4/6 of the last dialysis treatment sessions\n\nCarvedilol: Carvedilol 6.25 mg BID titrated weekly to maximum of 50 mg bid"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "25"}, {"groupId": "OG001", "value": "25"}]}], "classes": [{"title": "Baseline ALDH bright", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "25"}, {"groupId": "OG001", "value": "25"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.052", "lowerLimit": "0.042", "upperLimit": "0.076"}, {"groupId": "OG001", "value": "0.034", "lowerLimit": "0.017", "upperLimit": "0.08"}]}]}, {"title": "Follow up ALDH bright", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "25"}]}], "categories": [{"measurements": [{"groupId": "OG001", "value": "0.027", "lowerLimit": "0.013", "upperLimit": "0.048"}]}]}, {"title": "Baseline CD34/CD133 endothelial progenitor cells", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "25"}, {"groupId": "OG001", "value": "25"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.059", "lowerLimit": "0.036", "upperLimit": "0.070"}, {"groupId": "OG001", "value": "0.033", "lowerLimit": "0.016", "upperLimit": "0.051"}]}]}, {"title": "Follow up CD34/CD133", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "25"}]}], "categories": [{"measurements": [{"groupId": "OG001", "value": "0.029", "lowerLimit": "0.019", "upperLimit": "0.049"}]}]}]}, {"type": "SECONDARY", "title": "Flow Mediated Vasodilation", "description": "Measured as percent change in brachial artery diameter from baseline to post shear stress for an individual measurement. Follow up measurements were obtained in intervention subjects 12 weeks later", "populationDescription": "Follow up measurements were only obtained in intervention subjects receiving carvedilol", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "% dilation from baseline", "timeFrame": "12 weeks", "groups": [{"id": "OG000", "title": "Control", "description": "Patients without intradialytic hypertension defined as average pre to post hemodialysis SBP falling \\>10 mmhg for more than 4/6 of the last dialysis treatment sessions"}, {"id": "OG001", "title": "Intervention", "description": "Patients with intradialytic hypertension defined as average pre to post hemodialysis SBP elevation of \\>10 mmhg for more than 4/6 of the last dialysis treatment sessions\n\nCarvedilol: Carvedilol 6.25 mg BID titrated weekly to maximum of 50 mg bid"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "25"}, {"groupId": "OG001", "value": "25"}]}], "classes": [{"title": "Baseline FMD", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "25"}, {"groupId": "OG001", "value": "25"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.67", "spread": "1.24"}, {"groupId": "OG001", "value": "1.03", "spread": "0.7"}]}]}, {"title": "Follow Up FMD", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "25"}]}], "categories": [{"measurements": [{"groupId": "OG001", "value": "1.4", "spread": "0.84"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "First day of enrollment to end of study, an average 12 weeks", "eventGroups": [{"id": "EG000", "title": "Control", "description": "Patients without intradialytic hypertension defined as average pre to post hemodialysis SBP falling \\>10 mmhg for more than 4/6 of the last dialysis treatment sessions", "deathsNumAffected": 0, "deathsNumAtRisk": 25, "seriousNumAffected": 0, "seriousNumAtRisk": 25, "otherNumAffected": 0, "otherNumAtRisk": 25}, {"id": "EG001", "title": "Intervention", "description": "Patients with intradialytic hypertension defined as average pre to post hemodialysis SBP elevation of \\>10 mmhg for more than 4/6 of the last dialysis treatment sessions\n\nCarvedilol: Carvedilol 6.25 mg BID titrated weekly to maximum of 50 mg bid", "deathsNumAffected": 0, "deathsNumAtRisk": 25, "seriousNumAffected": 5, "seriousNumAtRisk": 25, "otherNumAffected": 22, "otherNumAtRisk": 25}], "seriousEvents": [{"term": "Gastroparesis", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 25}]}, {"term": "Pneumonia", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 25}]}, {"term": "Hemodialysis Access Revision", "organSystem": "Vascular disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 25}]}, {"term": "Fluid Overload", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 25}]}], "otherEvents": [{"term": "Symptomatic Intradialytic Hypotension", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "There were 22 episodes total out of 920 dialysis treatments among the 25 patients", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG001", "numEvents": 22, "numAffected": 22, "numAtRisk": 25}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Peter Van Buren", "organization": "University of Texas Southwestern Medical Center", "email": "peter.vanburen@utsouthwestern.edu", "phone": "214-645-8293"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-26"}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000077261", "term": "Carvedilol"}], "ancestors": [{"id": "D000000319", "term": "Adrenergic beta-Antagonists"}, {"id": "D000018674", "term": "Adrenergic Antagonists"}, {"id": "D000018663", "term": "Adrenergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000000975", "term": "Antioxidants"}, {"id": "D000020011", "term": "Protective Agents"}, {"id": "D000002121", "term": "Calcium Channel Blockers"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000077264", "term": "Calcium-Regulating Hormones and Agents"}, {"id": "D000014665", "term": "Vasodilator Agents"}, {"id": "D000058668", "term": "Adrenergic alpha-1 Receptor Antagonists"}, {"id": "D000000317", "term": "Adrenergic alpha-Antagonists"}], "browseLeaves": [{"id": "M1718", "name": "Carvedilol", "asFound": "Depressive Disorder", "relevance": "HIGH"}, {"id": "M3671", "name": "Adrenergic beta-Antagonists", "relevance": "LOW"}, {"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}, {"id": "M20755", "name": "Adrenergic Antagonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M4292", "name": "Antioxidants", "relevance": "LOW"}, {"id": "M21869", "name": "Protective Agents", "relevance": "LOW"}, {"id": "M5398", "name": "Calcium, Dietary", "relevance": "LOW"}, {"id": "M5381", "name": "Calcium", "relevance": "LOW"}, {"id": "M5384", "name": "Calcium Channel Blockers", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M17412", "name": "Vasodilator Agents", "relevance": "LOW"}, {"id": "M29194", "name": "Adrenergic alpha-1 Receptor Antagonists", "relevance": "LOW"}, {"id": "M3669", "name": "Adrenergic alpha-Antagonists", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "ChanBlk", "name": "Channel Blockers"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "BDCA", "name": "Bone Density Conservation Agents"}]}}, "hasResults": true}